 
 
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: BMN 111 | BMN-111 | Voxzogo®
                                 vosoritide is an approved drug (EMA & FDA (2021)) Compound class: 
                                                            Peptide
                                 
                                    
                                        Comment: Vosoritide is a cyclic analogue of C-type natriuretic peptide (CNP) that has a longer half-life (duration of action) than the endogenous peptide [1]. It comprises the 37 C-terminal amino acids from human CNP with the addition of proline and glycine (PG) at its N-terminal. Vosoritide represents a novel mechanism which has the potential to treat mutant fibroblast growth factor receptor 3-driven achondroplasia, by stimulating endochondral ossification and thereby ameliorating impaired bone growth [1-3]. | 
 | |||||||||||||||||
| Classification  | |
| Compound class | Peptide | 
| Approved drug? | Yes. EU EMA (2021) | US FDA (2021) | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 10022 | vosoritide | 
| Synonyms  | 
| BMN 111 | BMN-111 | Voxzogo® | 
| Database Links  | |
| CAS Registry No. | 1480724-61-5 (source: WHO INN record) | 
| GtoPdb PubChem SID | 315661153 | 
| PubChem CID | 119058036 | 
| Search Google for chemical match using the InChIKey | IGYWDDBBJPSOTG-WBAGYEQSSA-N | 
| Search Google for chemicals with the same backbone | IGYWDDBBJPSOTG | 
| Search PubMed clinical trials | vosoritide | 
| Search PubMed titles | vosoritide | 
| Search PubMed titles/abstracts | vosoritide | 
| UniChem Compound Search for chemical match using the InChIKey | IGYWDDBBJPSOTG-WBAGYEQSSA-N | 
| UniChem Connectivity Search for chemical match using the InChIKey | IGYWDDBBJPSOTG-WBAGYEQSSA-N |